High-Barrier Film Scale-Up: Patent Landscape 2026
- Filing activity peaked in 2017 at 20 families and has drifted down through a 2022 midpoint of 9, a pattern that reads as claim consolidation rather than a growing field.
- B32B layered-product claims dominate appearing in 207 of 247 families, with B29C shaping claims close behind at 139 — most filers are protecting laminate structure, not the deposition step itself.
- The United States and EPO carry the bulk of filings 84 and 69 records respectively, with WIPO PCT filings at only 22 — this is a two-jurisdiction fight, not a globally coordinated one.
Filing growth compares 2021 (4 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 247 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families combining high-barrier film language with scale-up process terms — roll-to-roll coating, coextrusion, vacuum deposition scale-up and high-throughput production — inside IPC classes B32B37 (laminating processes), B29C48 (extrusion/calendering) and C23C14 (vacuum coating). It captures the manufacturing side of barrier film, not raw material chemistry alone. Publication lags filing by roughly 18 months, so 2025-2026 counts will rise as records clear examination.
The 247 families span six receiving offices and eight IPC subclasses, giving a reasonably complete view of who is claiming laminate architecture versus who is claiming the process step that produces it.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and classification mix
Two views of the same 247 families: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.
Filing trend, 2017-2026
Filings peaked in 2017 at 20 and fell to a 2022 midpoint of 9, with 2026 still at 0 pending publication — consistent with a mature claim landscape rather than an emerging one.
IPC subclass composition
B32B (207) and B29C (139) dominate, meaning most protection sits on layered-product structure and plastics shaping rather than the coating step in C23C (68) — a gap worth checking before assuming deposition process claims are crowded.
Shares are the percentage of the 247 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on High-Barrier Film Scale-Up and Mass Production with Eureka
This page is one run against one query. Ask Eureka your own question about high-barrier film scale-up and mass production and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited prior art and a representative recent filing
Crystal Clear High Barrier Packaging Film — US20220161478A1
A transparent multilayer coextruded heat shrinkable barrier film for high-value food and medical device packaging. It combines transparent polyester outer layers with an inner nanolayer sequence alternating ethylene vinyl alcohol nanolayers with ethylene ethyl acrylate, LDPE or LLDPE nanolayers held below a specified crystallinity, joined by adhesive layers.Filed by BBS Corporation, published 2022-05-26 — filed under coextrusion process claims rather than a deposition or coating route.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20010038894A1 | Gas barrier film | 121 |
| 2 | US5558930A | Heat sealable, high moisture barrier film and method of making same | 95 |
| 3 | US5468526A | Multilayer barrier film for ostomy applications | 80 |
| 4 | US20080118749A1 | Barrier film for food packaging | 78 |
| 5 | US6218013B1 | Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative | 75 |
| 6 | US5492947A | Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative | 73 |
| 7 | US5061534A | High oxygen barrier film | 66 |
| 8 | US20050019503A1 | Gas barrier film | 65 |
| 9 | US5882565A | Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative | 59 |
| 10 | US5603974A | Barrier material comprising a thermoplastic and a compatible cyclodextrin derivative | 59 |
Citation counts favour older records that have had more time to accumulate citations inside this corpus — treat them as markers of influence on subsequent filers, not as evidence that the claims are still commercially active.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about where to focus
Three readings of the same dataset: the technology split, the geographic footprint, and the citation legacy that current filers are building against.
Laminate structure, not the coating step, carries the claim weight
B32B layered-product claims appear in 84% of families, well ahead of C23C vacuum-coating claims at 68. Filers are protecting the finished multilayer architecture far more often than the deposition equipment or process that builds it.
Protection is concentrated in two offices, not filed globally
The low PCT count relative to direct US and EPO filings suggests most applicants are defending core commercial markets rather than building broad international coverage — a gap for filers targeting Asia-Pacific production bases.
Volume has been declining since the 2017 peak
The midpoint year of 9 filings in 2022, against a 2017 peak of 20, points to a field where core claim territory was staked out early. New entrants face denser prior art than the raw filing count for any single recent year suggests.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to high-barrier film scale-up and mass production, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| NOVA Chemicals (International) S.A. | TIKUISIS TONY | 1 |
| NOVA Chemicals (International) S.A. | SAUVAGEAU DENNY PAUL | 1 |
| NOVA Chemicals (International) S.A. | MARSHALL SARAH | 1 |
| NOVA Chemicals (International) S.A. | LAM PATRICK | 1 |
| NOVA Chemicals (International) S.A. | CHUANG TINGTING | 1 |
| NOVA Chemicals (International) S.A. | CHISHOLM P SCOTT | 1 |
| NOVA Chemicals (International) S.A. | CHECKNITA DOUGLAS | 1 |
| NOVA Chemicals (International) S.A. | AUBEE NORMAN DORIEN JOSEPH | 1 |
Only 10 co-assignee pairs appear across 247 families, and the strongest links are single-instance collaborations tied to one applicant — this is a field of solo filers, not joint-venture consortia.
Who holds the claims, and where activity has stalled
Assignee momentum in the most recent year is flat across the board, which changes how a freedom-to-operate search should be scoped — recent silence does not mean the earlier claims have lapsed.
No leading assignee filed in the most recent year
NOVA Chemicals (International) S.A., Cryovac, Inc. and 3M Innovative Properties Company (USA) all show zero filings in the latest year tracked. Given the 18-month publication lag, this reads as a reporting gap as much as a real pause, but it means recent competitive signal from these names has to be inferred from older grants.
One major filer shows a clean year-over-year drop to zero
Dai Nippon Printing Co., Ltd. (Dai Nippon Printing) is the only assignee in this dataset with an explicit -100% YoY figure attached, moving from active filing to none in the latest tracked year — worth checking against its broader portfolio outside this search string before reading too much into it.
Collaboration is rare and concentrated on one applicant
NOVA Chemicals (International) S.A. anchors the three strongest co-assignee pairs in the dataset, each with individual named inventors rather than corporate co-filers. Elsewhere, the corpus is dominated by single-assignee filings.
| Assignee | Recent year | YoY |
|---|---|---|
| NOVA Chemicals (International) S.A. | 0 | — |
| Cryovac, Inc. | 0 | — |
| 3M Innovative Properties Company (USA) | 0 | — |
| Dai Nippon Printing Co., Ltd. | 0 | -100% |
| Stora Enso Oyj | 0 | — |
| Toyobo Co., Ltd. | 0 | — |
| OOO PKF Atlantis Pak | 0 | — |
| Aspen Research Corporation | 0 | — |
Where to take this analysis
The trend and classification data point to specific next steps depending on whether you are filing, licensing or scoping freedom to operate.
Run a freedom-to-operate check on coextrusion claims
With B29C claims present in 139 of 247 families, a targeted FTO pass on coextrusion die and layer-sequencing claims is the highest-value next step before committing to a production line design.
Explore in EurekaMap the C23C process-claim gap in detail
Vacuum deposition scale-up claims sit well behind structural laminate claims in volume. A closer read of the 68 C23C records will show whether that gap is real white space or simply under-indexed by this search string.
Explore in EurekaCommon questions about this landscape
This dataset covers families that combine high-barrier or barrier-film terminology with a scale-up process term — roll-to-roll coating, coextrusion, vacuum deposition scale-up, or high-throughput production — and that fall under IPC classes B32B37, B29C48 or C23C14. That means it captures the manufacturing and process side of barrier film specifically, not general barrier-material chemistry claims that lack a stated production route. A material composition patent with no scale-up language attached would not appear in this corpus.
The trend shows filings at 20 in 2017, falling to a midpoint of 9 by 2022, which is consistent with early claim staking followed by consolidation rather than continued growth. It does not necessarily mean interest in the technology has fallen; it more likely means the core structural and process claim space was substantially covered by the late 2010s. Note also that the 18-month publication lag means the most recent one to two years in any trend chart will always look lower than the true filing rate.
The United States (84 records) and the European Patent Office (69 records) together account for the large majority of filings in this corpus, well ahead of WIPO PCT filings at 22. A prior art or freedom-to-operate search should therefore start with US and EPO full-text databases rather than relying on PCT publications alone, since many applicants appear to be filing directly in their core commercial markets rather than pursuing broad international coverage.
The C23C coating and surface deposition subclass appears in 68 of 247 families, notably fewer than the 207 that touch B32B layered-product claims and the 139 that touch B29C shaping claims. That gap suggests process-level vacuum deposition claims are less densely occupied than structural laminate claims, though it is not proof of true white space — a deeper read of those 68 records is needed before filing to confirm the specific process steps still available.
Not necessarily. Companies including NOVA Chemicals (International) S.A., Cryovac, Inc. and 3M Innovative Properties Company (USA) all show zero filings in the most recent tracked year, but publication lag of roughly 18 months means recent applications from these companies may simply not have published yet. A more reliable read comes from looking at their filing history over several years rather than the single most recent data point, and from checking their portfolios outside this specific search string.
Research High-Barrier Film Scale-Up and Mass Production in depth with Eureka
Go past this page: query the whole high-barrier film scale-up and mass production corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.